Muhammad Abdel-Gawad

Prof. Muhammad Abdel-Gawad

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
AHAmro Metwaly Hassan
Amro Metwaly Hassan
MAMuhammad Abdel-Gawad
Muhammad Abdel-Gawad
AMAhmed Qasem Mohammed
Ahmed Qasem Mohammed
MHMustafa Ahmed Haridy
Mustafa Ahmed Haridy
KEKhaled Abd-El-Azeem Eid
Khaled Abd-El-Azeem Eid
Background: Helicobacter pylori infection is one of the most prevalent chronic bacterial human infections worldwide. Helicobacter pylori colonizes the gastric mucosa and causes persistent gastritis that may progress to gastric cancer. Increased resistance of H. pylori presents a major problem in most countries. Statins, including simvastatin, which are currently used to treat hypercholesterolemia, appear to have potential synergistic role to antibiotics. This study aimed to assess the value of adding simvastatin as adjuvant to standard triple therapy in patients infected with H. pylori. Methods: This study was conducted on 100 patients diagnosed with H. pylori by the presence of antigen in stools. All patients were randomly subjected either to the standard triple regimen (clarithromycin 500 mg bid + amoxicillin 1 g bid + omeprazole 20 mg bid) (group 1, N=50) or to the standard triple regimen plus simvastatin (clarithromycin 500 mg bid + amoxicillin 1 g bid + omeprazole 20 mg bid + simvastatin 20 mg bid) (group 2, N=50). Both groups were treated for 14 days and eradication of H. pylori was assessed by a stool antigen test 4 weeks after therapy. Results: Eradication of H. pylori infection was significantly higher in patients treated with the standard triple therapy plus simvastatin (n=41, 82%) than in patients treated with the standard triple therapy (n=31, 62%) (P<0.022). Conclusion: Simvastatin significantly improves the H. pylori eradication rate.

11 November 2022 in Annals of Medicine
Verified
Journal Article
Open access
MEMohamed Emara
Mohamed Emara
MZMariam Zaghloul
Mariam Zaghloul
MAMuhammad Abdel-Gawad
Muhammad Abdel-Gawad
NMNahed A. Makhlouf
Nahed A. Makhlouf
MAMohamed Abdelghani
Mohamed Abdelghani
MAMohamed Alboraie
Mohamed Alboraie
Since the emergence of the novel corona virus (SARS-Cov-2) in the late 2019 and not only the endoscopy practice and training but also the health care systems around the globe suffers. This systemat...

16 March 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AHAmro M. Hassan
Amro M. Hassan
MHMustafa Ahmed Haridy
Mustafa Ahmed Haridy
MSMohamed Z. Shoaeir
Mohamed Z. Shoaeir
TATarek M. Abdel-Aziz
Tarek M. Abdel-Aziz
MQMohamed Khairy Qura
Mohamed Khairy Qura
MAMuhammad Abdel-Gawad
Muhammad Abdel-Gawad
Nonalcoholic fatty liver disease (NAFLD) has been linked with a number of extra hepatic diseases and could be a potential risk factor of decreasing bone mineral density. To determine whether Upper Egyptian patients with NAFLD are at risk of developing osteoporosis. Cross sectional study was done on a total 100 individuals; 50 patients diagnosed with NAFLD (based on ultrasound imaging) crossed-matched with 50 individuals without NAFLD based on age, sex and body mass index. Bone mineral density, serum calcium and phosphorus levels, serum parathyroid hormone, serum vitamin D and fasting insulin level were assessed. Osteoporosis was prevalent in NAFLD patients versus to controls (19/50 vs. 0/50; P < 0.001). There was significant decrease in bone mineral density in NAFLD patients than controls (− 2.29 ± 0.4 vs. − 1.53 ± 0.1; P < 0.001). There was a statistical significance decrease in serum vitamin D and calcium levels in NAFLD patients than controls. Furthermore, vitamin D levels in the NAFLD group was a predictor for osteoporosis (OR 0.614; 95% CI 0.348–0.825). Patients with NAFLD tend to have a significant decrease in bone density, vitamin D, and serum calcium levels than controls.

27 September 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
NINagat Ibrahim
Nagat Ibrahim
EKEkram M. Abdel Khalek
Ekram M. Abdel Khalek
NMNahed A. Makhlouf
Nahed A. Makhlouf
MAMuhammad Abdel-Gawad
Muhammad Abdel-Gawad
MMMohamed Mekky
Mohamed Mekky
MAMohamed Alboraie
Mohamed Alboraie
There is a lack of epidemiological data on fascioliasis in Egypt regarding disease characteristics and treatment outcomes across different governorates. We aimed to identify the demographic, epidemiologic, clinical, laboratory, and radiological characteristics and treatment outcomes of patients diagnosed with fascioliasis in Egypt. Data on human fascioliasis were collected retrospectively from patients’ medical records in the period between January 2018 and January 2020. The study included 261 patients. More than 40% of enrolled patients were in the age group of 21–40 years old. Geographically, 247 (94.6%) were from Assiut Governorate with 69.3% were from rural areas. The most frequent symptoms were right upper quadrant pain (96.9%), and fever (80.1%). Eosinophilia was found in 250 cases (95.8%). Hepatic focal lesions were detected in 131 (50.2%); out of them 64/131 (48.9%) had a single lesion. All patients received a single dose of 10 mg/kg of triclabendazole, 79.7% responded well to a single dose, while in 20.3% a second ± a third dose of treatment was requested. After therapy, there was a reduction in leucocytes, Fasciola antibodies titer, eosinophilic count, bilirubin, and liver enzymes with an increase in hemoglobin level. According to our findings, a high index of suspicion should be raised in cases with fever, right upper abdominal pain, and peripheral eosinophilia, and further imaging workup is mandated to detect hepatic focal lesions. Prompt treatment by triclabendazole can serve as a standard-of-care regimen even for suspected cases.

5 March 2022 in Liver International
Verified
Journal Article
Closed access
MAMuhammad Abdel-Gawad
Muhammad Abdel-Gawad
SASherief Abd‐Elsalam
Sherief Abd‐Elsalam
IAIbrahim Abdel‐Gawad
Ibrahim Abdel‐Gawad
MTMohammed Tag‐Adeen
Mohammed Tag‐Adeen
MEMarwa El‐Sayed
Marwa El‐Sayed
DADalia Abdel‐Malek
Dalia Abdel‐Malek

6 March 2019 in Journal of Ultrasound
Verified
Journal Article
Closed access
PDF file
MAMuhammad Abdel-Gawad
Muhammad Abdel-Gawad
AEAhmed Samir Abd Eltawab
Ahmed Samir Abd Eltawab
AAAhmed Abd-Elrady Ahmed
Ahmed Abd-Elrady Ahmed